{"id":5626,"date":"2024-06-13T16:28:05","date_gmt":"2024-06-13T16:28:05","guid":{"rendered":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/?p=5626"},"modified":"2024-06-14T01:09:12","modified_gmt":"2024-06-14T01:09:12","slug":"aznarez","status":"publish","type":"post","link":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/aznarez\/","title":{"rendered":"Isabel Aznarez, PhD"},"content":{"rendered":"<p><img decoding=\"async\" class=\"lazyload alignnone size-full wp-image-5627\" src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Isabel-Aznarez.png\" data-orig-src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Isabel-Aznarez.png\" alt=\"\" width=\"300\" height=\"300\" srcset=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27300%27%20height%3D%27300%27%20viewBox%3D%270%200%20300%20300%27%3E%3Crect%20width%3D%27300%27%20height%3D%27300%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-srcset=\"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Isabel-Aznarez-66x66.png 66w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Isabel-Aznarez-150x150.png 150w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Isabel-Aznarez-200x200.png 200w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Isabel-Aznarez.png 300w\" data-sizes=\"auto\" data-orig-sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>Isabel Aznarez is senior vice president of Discovery Research and a co-founder at Stoke Therapeutics. Isabel has extensive experience in human genetics, RNA metabolism and modulation of RNA processes using antisense oligonucleotides. Prior to founding Stoke Therapeutics, she was a research investigator with Professor Adrian Krainer, whose lab she joined as a postdoctoral fellow in 2008. Previously, Isabel was a researcher at the Hospital for Sick Children with Professor Lap-Chee Tsui, where she focused on the effect of cystic fibrosis mutations on the splicing of the CFTR gene. Isabel holds a Ph.D. in molecular and medical genetics from the University of Toronto and a B.Sc. in biology and human genetics from the University of Uruguay.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Isabel Aznarez is senior vice president of Discovery Research and a co-founder at Stoke Therapeutics. Isabel has extensive experience in human genetics, RNA metabolism and modulation of RNA processes using antisense oligonucleotides. Prior to founding Stoke Therapeutics, she was a research investigator with Professor Adrian Krainer, whose lab she joined as a postdoctoral fellow in [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5627,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-5626","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-creative"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/comments?post=5626"}],"version-history":[{"count":1,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5626\/revisions"}],"predecessor-version":[{"id":5628,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5626\/revisions\/5628"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media\/5627"}],"wp:attachment":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media?parent=5626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/categories?post=5626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/tags?post=5626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}